Quest plans to refine, develop and validate the technology and is aiming to launch the test in North America next year.

Quest Diagnostics Incorporated (NYSE:DGX), a prominent provider of diagnostic testing and information services, has hit a record-breaking share price of $180.11, pushing the company’s market ...

Robert W. Baird analyst Eric Coldwell maintained a Buy rating on McKesson (MCK – Research Report) today and set a price target of $797.00. The company’s shares opened today at ...